-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
Get ABVC BioPharma alerts:Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.
ABVC BioPharma Stock Performance
Shares of ABVC stock opened at $0.78 on Thursday. The company's fifty day simple moving average is $0.75 and its 200-day simple moving average is $0.79. ABVC BioPharma has a 52 week low of $0.50 and a 52 week high of $3.13. The company has a market cap of $25.45 million, a PE ratio of -1.15 and a beta of 0.50.ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.
About ABVC BioPharma
(Get Rating)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
See Also
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
ABVC BioPharma, Inc.（OTCMKTS: ABVC — 获取评级）——Zacks Small Cap在1月18日星期三发布的一份报告中公布了ABVC BioPharma的2023年第一季度每股收益估计。Zacks Small Cap分析师M. Marin预计，该公司将在本季度公布每股收益（0.05美元）。ABVC BioPharma当前全年收益的共识估计为每股收益（0.56美元）。Zacks Small Cap还公布了ABVC BioPharma2023年第二季度每股收益（0.06美元）、2023年第三季度收益为每股收益（0.05美元）和2023年第四季度每股收益（0.04美元）的估计。
Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.
另外，Maxim集团在11月16日星期三的一份研究报告中将ABVC BioPharma的股票评级从 “买入” 下调至 “持有”。
ABVC BioPharma Stock Performance
ABVC BioPharma 股票表现
ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.
ABVC BioPharma（OTCMKTS: ABVC — 获取评级）最后一次公布季度财报是在11月14日星期一。该公司公布了本季度每股收益（0.11美元），比分析师的共识预期（0.20美元）高出0.09美元。该公司本季度的收入为4万美元，而分析师的预期为03万美元。
About ABVC BioPharma
关于 ABVC BioPharma
(Get Rating)
（获取评分）
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
ABVC BioPharma, Inc是一家临床阶段的生物制药公司，开发药物和医疗器械，以满足美国未得到满足的医疗需求。该公司正在开发一种治疗三阴性乳腺癌的联合疗法 ABV-1501，该药物正处于 I/II 期临床试验；ABV-1504 已完成重度抑郁症的 II 期临床试验；ABV-1505 正在进行注意力缺陷多动障碍的 II 期临床试验；ABV-1703 已经完成了治疗骨髓增生异常综合征的 I 期临床试验；ABV-1601 正在进行治疗骨髓增生异常综合征的 I 期临床试验；正在进行治疗 I/II 期临床试验癌症患者的抑郁症；以及 ABV-1702ABV-1701 Vitargus 用于治疗视网膜脱离或玻璃体出血。
See Also
另见
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取 StockNews.com 关于 ABVC BioPharma（ABVC）的研究报告的副本
- MarketBeat Week 回顾 — 1/16 — 1/20
- Old Dominion 是否表明卡车运输正在刹车？
- 诺德斯特龙将对降价的恐惧带入零售业
- 埃克森美孚股票：距离买入点仅几步之遥
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 ABVC BioPharma Daily 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收ABVC BioPharma及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧